Images List Premium Download Classic

Autoimmune Diseases

Autoimmune Diseases-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and ...
Nuevolution A/s
November 30, 2017 - N°20170342074

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
Diaryl macrocycles as modulators of protein kinases
Tp Therapeutics, Inc.
November 23, 2017 - N°20170334929

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Crystalline forms of a bruton's tyrosine kinase inhibitor
Pharmacyclics Llc
November 23, 2017 - N°20170334921

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other ...
Autoimmune Diseases Patent Pack
Download 177+ patent application PDFs
Autoimmune Diseases Patent Applications
Download 177+ Autoimmune Diseases-related PDFs
For professional research & prior art discovery
inventor
  • 177+ full patent PDF documents of Autoimmune Diseases-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Antioxidant composition containing extracellular polysaccharide produced using ceriporia lacerata as active ingredient
Fugenbio Co., Ltd.
November 23, 2017 - N°20170333501

The present invention relates to an antioxidant composition containing an extracellular polysaccharide produced using ceriporia lacerata, or a mycelium culture of ceriporia lacerata comprising the same, or a dry powder or an extract thereof as an active ingredient. The composition can be used as an antioxidant for preventing or treating various diseases such as brain diseases such as stroke, parkinson's ...
Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound ...
The Catholic University Of Korea Industry-academic Cooperation Foundation
November 23, 2017 - N°20170333370

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of il-17 and tnf-α, which are inflammatory cytokines, increases the activity of regulatory t cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune ...
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
Delinia, Inc.
November 16, 2017 - N°20170327555

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fe protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs. The fe moiety provides a ...
Autoimmune Diseases Patent Pack
Download 177+ patent application PDFs
Autoimmune Diseases Patent Applications
Download 177+ Autoimmune Diseases-related PDFs
For professional research & prior art discovery
inventor
  • 177+ full patent PDF documents of Autoimmune Diseases-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of cyclin-dependent kinase 7 (cdk7)
Nuevolution A/s
November 16, 2017 - N°20170327496

The present invention provides novel compounds of formula (i) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in ...
Methods of treating autoimmune diseases
Genzyme Corporation
November 16, 2017 - N°20170326203

Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e. G., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells. ...
Treatment of allergies and autoimmune diseases
Genzyme Corporation
November 16, 2017 - N°20170326029

The present disclosure provides a method of treating allergies and autoimmune diseases using microsystem acupuncture. Methods provided herein for treating allergies and autoimmune diseases using microsystem acupuncture involving a novel allergy zone. In embodiments, the method includes identifying an allergy zone (az) (soliman allergy zone (saz)) (fig. 1a) in an acupuncture microsystem of a subject in need of treatment and ...
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
Ono Pharmaceutical Co., Ltd.
November 09, 2017 - N°20170320949

Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a pd-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in ...
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
Novo Nordisk A/s
November 09, 2017 - N°20170320946

Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed. Trem-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by ...
Compositions comprising bacterial strains
4d Pharma Research Limited
November 09, 2017 - N°20170319634

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
Immunosuppressive blood cells and methods of producing the same
Universitatsklinikum Heidelberg
November 09, 2017 - N°20170319619

The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.
Autoimmune Diseases Patent Pack
Download 177+ patent application PDFs
Autoimmune Diseases Patent Applications
Download 177+ Autoimmune Diseases-related PDFs
For professional research & prior art discovery
inventor
  • 177+ full patent PDF documents of Autoimmune Diseases-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating autoimmune disease using a domain antibody directed against cd40l
Bristol-myers Squibb Company
October 26, 2017 - N°20170306034

Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (itp), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose ...
Anti-cd100 antibodies and methods for using the same
Vaccinex, Inc.
October 26, 2017 - N°20170306017

Compositions and methods are provided for treating diseases associated with cd100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-cd100 monoclonal antibodies have been developed to neutralize cd100.
Il22 immunoconjugates
Philogen S.p.a.
October 26, 2017 - N°20170305989

The application relates to a conjugate comprising interleukin-22 (il22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ed-a isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (ibd).
Crystalline forms of a bruton's tyrosine kinase inhibitor
Pharmacyclics Llc
October 26, 2017 - N°20170305919

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other ...
Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 26, 2017 - N°20170304441

Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination ...
Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection
Rappaport Family Institute For Research In The Medical Sciences
October 26, 2017 - N°20170304436

The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor b-i, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.
Metallic gold cluster molecules as therapeutic agents for arthritic animals
Rappaport Family Institute For Research In The Medical Sciences
October 26, 2017 - N°20170304408

A therapeutic method for attenuating symptoms of inflammation and autoimmune diseases. This method includes preparing and administering to animals intraperitoneally or orally a metallic gold cluster complex preparation.
Methods for increasing the selective efficacy of gene therapy using car peptide and heparan sulfate ...
Vascular Biosciences
October 26, 2017 - N°20170304389

Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune ...
Loading